Virology of the post-polio syndrome

Future Virology

Volumn 2, Issue 2, 2007, Pages 183-192

  Baj, Andreina ^a   Monaco, Salvatore ^b   Zanusso, Gianluigi ^b   Dall'Ora, Elisa ^b   Bertolasi, Laura ^b   Toniolo, Antonio ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Antivirals; Diagnosis; Enteroviruses; Nucleic acid detection; Pathogenesis; Picornaviruses; Viral antigens; Virus persistence

Indexed keywords

5 NITROCYTIDINE TRIPHOSPHATE; ALPHA INTERFERON; ANTIVIRUS AGENT; BTA 188; CD155 ANTIGEN; DISOXARIL; DNA FRAGMENT; ENVIROXIME; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PIRODAVIR; PLECONARIL; PYRROLIDINE DITHIOCARBAMATE; RIBAVIRIN; RUPINTRIVIR; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOPATHOLOGY; DRUG POTENTIATION; ENTEROVIRUS; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; GENE SILENCING; GENE STRUCTURE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MUTAGENIC ACTIVITY; NONHUMAN; OPEN READING FRAME; PATHOGENESIS; PERSISTENT VIRUS INFECTION; POLIOMYELITIS; POLIOMYELITIS VIRUS; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA VIRUS; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ENTEROVIRUS; POLIOVIRUS;

EID: 34249311307     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.2.183     Document Type: Review

References (70)

1. Farbu E, Gilhus NE, Barnes MP et al.: EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur. J. Neurol. 13, 795-801 (2006).
2. Trojan DA, Cashman NR: Post-poliomyelitis syndrome. Muscle Nerve 31, 6-19 (2005).
3. Julien J, Leparc-Goffart I, Lina B et al.: Postpolio syndrome: poliovirus persistence is involved in the pathogenesis. J. Neurol. 246, 472-476 (1999).
4. Agol VI: Molecular mechanisms of poliovirus variation and evolution. Curr. Top. Microbiol. Immunol. 299, 211-259 (2006).
5. Palacios G, Oberste MS: Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11, 424-433 (2005).
6. Mendelsohn CL, Wimmer E, Racaniello VR: Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56, 855-865 (1989).
7. Pende D, Castriconi R, Romagnani P et al.: Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107, 2030-2036 (2006).
8. Koike S, Ise I, Sato Y, Yonekawa H, Gotoh O, Nomoto A: A second gene for the African green monkey poliovirus receptor that has no putative NM-glycosylation site in the functional N-terminal immunoglobulin-like domain. J. Virol. 66, 7059-7066 (1992).
9. Nagata N, Iwasaki T, Ami Y et al.: A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. Virology 321, 87-100 (2004).
10. Ohka S, Matsuda N, Tohyama K et al.: Receptor (CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome. J. Virol. 78, 7186-7198 (2004).
11. Kauder S, Kan S, Racaniello VR: Age-dependent poliovirus replication in the mouse central nervous system is determined by internal ribosome entry site-mediated translation. J. Virol. 80, 2589-2595 (2006).
12. Ida-Hosonuma M, Iwasaki T, Yoshikawa T et al.: The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 79, 4460-4469 (2005).
13. Pause A, Methot N, Svitkin Y, Merrick WC, Sonenberg N: Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. EMBO J. 13, 1205-1215 (1994).
14. Ray PS, Das S: La autoantigen is required for the internal ribosome entry site-mediated translation of Coxsackievirus B3 RNA. Nucleic Acids Res. 30, 4500-4508 (2002).
15. Joachims M, van Breugel PC, Lloyd RE: Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J. Virol. 73, 718-727 (1999).
16. Baj A, Bettaccini A, Nishimura T, Onodera T, Toniolo A: Poliovirus type 1 infection of murine PRNP-knockout neuronal cells. J. Neurovirol. 11, 237-246 (2005).
17. Pavio N, Buc-Caron MH, Colbere-Garapin F: Persistent poliovirus infection of human fetal brain cells. J. Virol. 70, 6395-6401 (1996).
18. Wahid R, Cannon MJ, Chow M: Dendritic cells and macrophages are productively infected by poliovirus. J. Virol. 79, 401-409 (2005).
19. Buenz EJ, Howe CL: Picornaviruses and cell death. Trends Microbiol. 14, 28-36 (2006).
20. Joachims M Harris KS, Etchison D: Poliovirus protease 3C mediates cleavage of microtubule-associated protein 4. Virology 211, 451-461 (1995).
21. Koyama AH, Irie H, Ueno F, Ogawa M, Nomoto A, Adachi A: Suppression of apoptotic cell death by poliovirus. J. Gen. Virol. 82, 2965-2972 (2001).
22. Neznanow N, Chumakov KP, Ullrich A, Agol VI, Gudkov AV: Unstable receptors disappear from cell surface during poliovirus infection. Med. Sci. Monit. 8, BR391-BR396 (2002).
23. Pozner RG, Berria MI, Negrotto S, Schattner M, Gomez RM: Differential astrocyte response to Theiler's murine encephalomyelitis virus infection. Intervirology 48, 279-284 (2005).
24. Bodian D: Histopathological basis of clinical findings in poliomyelitis. Am. J. Med. 6, 563-578 (1949).
25. Bruno RL, Frick NM, Cohen J: Polioencephalitis, stress, and the etiology of post-polio sequelae. Orthopedics 14, 1269-1276 (1991).
26. Girard S, Couderc T, Destombes J, Thiesson D, Delpeyroux F, Blondel B: Poliovirus induces apoptosis in the mouse central nervous system. J. Virol. 73, 6066-6072 (1999).
27. Miller DC: Post-polio syndrome spinal cord pathology. Case report with immunopathology. Ann. NY Acad. Sci. 753, 186-193 (1995).
28. Yang CF, Chen HY, Jorba J et al.: Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79, 12623-12634 (2005).
29. MacLennan C, Dunn G, Huissoon AP et al.: Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363, 1509-1513 (2004).
30. Labadie K, Pelletier I, Saulnier A, Martin J, Colbere-Garapin F: Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology 318, 66-78 (2004).
31. Gosselin AS, Simonin Y, Guivel-Benhassine F et al.: Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells. J. Virol. 77, 790-798 (2003).
32. Conaldi PG, Biancone L, Botelli A, de Martino A, Camussi G, Toniolo A. Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J. Virol. 71, 9180-9187 (1997).
33. Conaldi PG, Serra C, Mossa A et al.: Persistent infection of human vascular endothelial cells by group B coxsackieviruses. J. Infect. Dis. 175, 693-696 (1997).
34. Zanone MM, Favaro E, Conaldi PG et al.: Persistent infection of human microvascular endothelial cells by coxsackie B viruses induces increased expression of adhesion molecules. J. Immunol. 171, 438-446 (2003).
35. Nishiwaki T, Ina K, Goto H et al.: Possible involvement of the interleukin-15 and interleukin-15 receptor system in an heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J. Gastroenterol. 40, 128-136 (2005).
36. Ylipaasto P, Kutlu B, Rasilainen S et al.: Global profiling of coxsackieviruses- and cytokine-induced gene expression in human pancreatic islets. Diabetologia 48, 1510-1522 (2005).
37. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R: Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348 (2006).
38. Pfeiffer JK, Kirkegaard K: Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain. Proc. Natl Acad. Sci. USA 103, 5520-5525 (2006).
39. Girard S, Gosselin AS, Pelletier I, Colbere-Garapin F, Couderc T, Blondel B: Restriction of poliovirus RNA replication in persistently infected nerve cells. J. Gen. Virol. 83, 1087-1093 (2002).
40. Minor PD: Polio eradication, cessation of vaccination and re-emergence of disease. Nat. Rev. Microbiol. 2, 473-482 (2004).
41. Yakovenko ML, Cherkasova EA, Rezapkin GV et al.: Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80, 2641-2653 (2006).
42. Fiore L, Ridolfi B, Genovese D et al.: Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J. Virol. 71, 6905-6912 (1997).
43. + cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J. Virol. 79, 5988-5995 (2005).
44. Marttila J, Hyoty H, Vilja P et al.: T-cell epitopes in coxsackievirus B4 structural proteins concentrate in regions conserved between enteroviruses. Virology 293, 217-224 (2002).
45. Triantafilou K, Orthopoulos G, Vakakis E et al.: Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly toll-like receptor (TLR) 8-dependent. Cell Microbiol. 7, 1117-1126 (2005).
46. Spotnitz MD, Lesch M: Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog. Cardiovasc. Dis. 49, 42-57 (2006).
47. Gordon T, Hegedus J, Tam SL: Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol. Res. 26, 174-185 (2004).
48. Thomas CK, Zijdewind I: Fatigue of muscles weakened by death of motoneurons. Muscle Nerve 33, 21-41 (2006).
49. Dalakas MC, Elder G, Hallett M et al.: A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. N. Engl. J. Med. 31, 959-963 (1986).
50. Kaminski HJ, Tresser N, Hogan RE, Martin E: Spinal cord histopathology in long-term survivors of poliomyelitis. Muscle Nerve 18, 1208-1209 (1995).
51. Sharief MK, Hentges R, Ciardi M: Intrathecal immune response in patients with the postpolio syndrome. N. Engl. J. Med. 325, 749-755 (1991).
52. Muir P, Nicholson F, Sharief MK et al.: Evidence for persistent enterovirus infection of the central nervous system in patients with previous paralytic poliomyelitis. Ann. NY Acad. Sci. 753, 219-232 (1995).
53. Leon-Monzon ME, Dalakas MC: Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Ann. NY Acad. Sci. 753, 208-218 (1995).
54. Leparc-Goffart I, Julien J, Fuchs F, Janatova I, Aymard M, Kopecka H: Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with postpolio syndrome. J. Clin. Microbiol. 34, 2023-2026 (1996).
55. Goodall EF, Morrison KE: Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev. Mol. Med. 8, 1-22 (2006).
56. Pun S, Santos AF, Saxena S, Xu L, Caroni P: Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9, 408-419 (2006).
57. Racaniello VR: One hundred years of poliovirus pathogenesis. Virology 344, 9-16 (2006).
58. Tam PE: Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 19, 133-146 (2006).
59. Lammi N, Karvonen M, Tuomilehto J: Do microbes have a causal role in Type 1 diabetes? Med. Sci. Monitor 11, RA63-RA69 (2005).
60. Ravits J: Sporadic amyotrophic lateral sclerosis: a hypothesis of persistent (non-lytic) enteroviral infection. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6, 77-87 (2005).
61. Barnard DL: Current status of anti-picornavirus therapies. Curr. Pharm. des. 12, 1379-1390 (2006).
62. Rotbart HA, Webster AD: Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 32(2), 228-235 (2001).
63. Barnard DL, Hubbard VD, Since DF et al.: In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to Pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 48(5), 1766-1772 (2004).
64. Witherell G: AG-7088 Pfizer. Curr. Opin. Investig. Drugs 1, 297-302 (2000).
65. Crotty S, Maag D, Arnold JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6, 1375-1379 (2000).
66. Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR: Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem. 49, 6166-6169 (2006).
67. Nikolaeva L, Galabov AS: Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Acta. Virol. 39, 235-41 (1995).
68. Saulnier A, Pelletier I, Labadie K, Colbere-Garapin F: Complete cure of persistent virus infections by antiviral siRNAs. Mol. Ther. 13(1), 142-50 (2006).
69. Si X, McManus BM, Zhang J et al.: Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J. Virol. 79, 8014-8023 (2005).
70. Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K: Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial Lancet Neurol. 5, 493-500 (2006).